RLAY News and Press, Relay Therapeutics Inc. From 11/03/23

Relay Therapeutics Inc. (RLAY) is expected to report $-0.83 for Q3 2023

2023-11-03 01:07:35 ET More on Relay Therapeutics Relay Therapeutics surges 13% on early-stage data on tumors asset Seeking Alpha’s Quant Rating on Relay Therapeutics For further details see: Relay Therapeutics GAAP EPS of -$0.54, revenue of $25.2M

Reported initial RLY-4008 (lirafugratinib) data demonstrating durable responses across multiple FGFR2-altered solid tumors Announced plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet combinations in HR+/HER2- breast cancer by YE 2023 Updated pipeline to extend cash runwa...

CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2023 financial resu...

2023-10-13 15:00:54 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

2023-10-12 19:15:54 ET More on Relay Therapeutics Relay Therapeutics: Market May Be Prematurely Dismissing RLY-2608 Seeking Alpha’s Quant Rating on Relay Therapeutics Historical earnings data for Relay Therapeutics Financial information for Relay Thera...

2023-10-12 17:48:17 ET Gainers: Comtech Telecommunications  ( CMTL ) +14% . Relay Therapeutics ( RLAY ) +12% . Ovid Therapeutics  ( OVID ) +6% . Groupon ( GRPN ) +5% . Omeros Corporation ( OMER ) +4% . Losers: O...

35% ORR in patients with FGFR2 fusions (excluding CCA) & 40% ORR in patients with FGFR2-altered HR+/HER2- breast cancer RLY-4008 commercialization plans to focus on broader tumor agnostic opportunities Clinical focus on PI3Kα mutant selective programs, with plans to i...

CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lira...

2023-08-08 16:32:54 ET Relay Therapeutics press release ( NASDAQ: RLAY ): Q2 GAAP EPS of -$0.81 beats by $0.01 . Revenue of $0.12M (-67.6% Y/Y) misses by $0.59M . For further details see: Relay Therapeutics GAAP EPS of -$0.81 beats by $0.01, revenue of $0...